Treatment of patients with chronic myeloid leukaemia (CML) has become increasingly difficult in recent years due to the variety of treatment options available and challenge deciding on the most appropriate treatment strategy for an individual patient. To facilitate the treatment strategy decision, disease assessment should involve molecular response to initial treatment for an individual patient. Patients predicted not to achieve major molecular response (MMR) at 24 months to frontline imatinib may be better treated with alternative frontline therapies, such as nilotinib or dasatinib. The aims of this study were to i) understand the clinical prediction ‘rules’ for predicting MMR at 24 months for CML patients treated with imatinib using clin...
Treatment of BCR-ABL1⁺ human leukemia, especially for early phase chronic myeloid leukemia (CML) pat...
In the face of competing first-line treatment options for CML, early prediction of prognosis on imat...
Background Second-generation tyrosine kinase inhibitors induce cytogenetic responses in approximatel...
BACKGROUND:Treatment of patients with chronic myeloid leukaemia (CML) has become increasingly diffic...
BACKGROUND: Treatment of patients with chronic myeloid leukaemia (CML) has become increasingly diffi...
<p><b>Objective:</b> Until recently, imatinib was the standard first-line treatment in chronic myelo...
Imatinib has undoubtedly revolutionised the treatment of chronic myeloid leukaemia (CML) and hence h...
The purpose was to assess predictive factors for outcome in patients with chronic myeloid leukemia (...
The purpose was to assess predictive factors for outcome in patients with chronic myeloid leukemia (...
PURPOSE Deep molecular response (MR(4.5)) defines a subgroup of patients with chronic myeloid leu...
Chronic Myeloid Leukemia is a kind of blood cancer with around 1 incidence per 100 000 persons/year....
We explored the impact of early molecular response (EMR; BCR-ABL 10%) on imatinib (33%) than on nilo...
BACKGROUND:The achievement of a sustained deep molecular response is a goal of increasing relevance ...
PURPOSE: The achievement of a major molecular response (MMolR) at 12 months is a surrogate marker of...
A retrospective study was performed to describe molecular responses (MR) on the international scale ...
Treatment of BCR-ABL1⁺ human leukemia, especially for early phase chronic myeloid leukemia (CML) pat...
In the face of competing first-line treatment options for CML, early prediction of prognosis on imat...
Background Second-generation tyrosine kinase inhibitors induce cytogenetic responses in approximatel...
BACKGROUND:Treatment of patients with chronic myeloid leukaemia (CML) has become increasingly diffic...
BACKGROUND: Treatment of patients with chronic myeloid leukaemia (CML) has become increasingly diffi...
<p><b>Objective:</b> Until recently, imatinib was the standard first-line treatment in chronic myelo...
Imatinib has undoubtedly revolutionised the treatment of chronic myeloid leukaemia (CML) and hence h...
The purpose was to assess predictive factors for outcome in patients with chronic myeloid leukemia (...
The purpose was to assess predictive factors for outcome in patients with chronic myeloid leukemia (...
PURPOSE Deep molecular response (MR(4.5)) defines a subgroup of patients with chronic myeloid leu...
Chronic Myeloid Leukemia is a kind of blood cancer with around 1 incidence per 100 000 persons/year....
We explored the impact of early molecular response (EMR; BCR-ABL 10%) on imatinib (33%) than on nilo...
BACKGROUND:The achievement of a sustained deep molecular response is a goal of increasing relevance ...
PURPOSE: The achievement of a major molecular response (MMolR) at 12 months is a surrogate marker of...
A retrospective study was performed to describe molecular responses (MR) on the international scale ...
Treatment of BCR-ABL1⁺ human leukemia, especially for early phase chronic myeloid leukemia (CML) pat...
In the face of competing first-line treatment options for CML, early prediction of prognosis on imat...
Background Second-generation tyrosine kinase inhibitors induce cytogenetic responses in approximatel...